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Abstract
Background: Virus-Like Particles (VLPs) represent an efficient strategy to present and deliver conformational
antigens to the immune system, inducing both arms of the adaptive immune response. Moreover, their particulate
structure surrounded by cell membrane provides an adjuvanted effect to VLP-based immunizations. In the present
study, the elicitation of different patterns of IgG subclasses by VLPs, administered in CpG ODN1826 or poly(I:C)
adjuvants, has been evaluated in an animal model.
Results: Adjuvanted VLPs elicited a higher titer of total specific IgG compared to VLPs alone. Furthermore, while
VLPs alone induced a balanced TH2 pattern, VLPs formulated with either adjuvant elicited a TH1-biased IgG
subclasses (IgG2a and IgG3), with poly(I:C) more potent than CpG ODN1826.
Conclusions: The results confirmed that adjuvants efficiently improve antigen immunogenicity and represent a
suitable strategy to skew the adaptive immune response toward the differentiation of the desired T helper subset,
also using VLPs as antigen.
Introduction
The development of a safe and effective HIV-1 vaccine,
either prophylactic or therapeutic, remains a major con-
cern and a high priority for the scientific community. In
this respect, given that strategies based on attenuated or
inactivated pathogens are not suitable as HIV vaccines
for safety reasons, alternative effective vaccination strate-
gies are developed and evaluated [1].
In this framework, Virus-Like Particles represent a
highly attractive type of subunit vaccine since they are
self-assembling, non-replicating, non-pathogenic parti-
cles, similar in size and conformation to intact virions
[2]. Moreover, VLPs can enter both MHC class I and
class II antigen processing pathways in antigen present-
ing cells [3,4], eliciting both humoral and cellular
immune responses [5]. VLP vaccines have been devel-
oped and licensed for HBV as well as HPV and immu-
nological studies have showed induction of protective
humoral and cellular immunity [6-8]. Additional VLP
based vaccine for other viruses such as HCV, influenza
virus and HIV-1 are in different stages of pre-clinical
and clinical trial [9-15].
Human IgG consists of four subclasses contributing in
different ways to humoral immunity against pathogens.
Individual subclasses are elicited by different type of
antigens: antibody responses to viral and bacterial pro-
tein antigens are mainly restricted to IgG1 and IgG3
[16-19], while IgG2 is generally produced in response to
carbohydrate antigens [20-22]. In this regards, subjects
with decreased levels of IgG2 antibodies show poor anti-
body responses to polysaccharide vaccines [23], suggest-
i n gt h i ss u b c l a s si sr e s p o n s i b l ef o rp r o t e c t i o na g a i n s t
encapsulated pathogens. In addition, several factors,
including the structure and quantity of antigen [24] as
well as the route and duration of antigenic stimulation
may affect the subclass of IgG antibody produced. In
particular, IgG1 and IgG3 subclasses mediate important
protective, biological functions such as complement fixa-
tion, opsonization and induction of ADCC by NK cells
[25,26].
Mice, similarly to humans, show four different classes
of IgGs, named IgG1, IgG2a, IgG2b and IgG3, which
functionally correspond to the human IgG1, IgG2, IgG4
and IgG3, respectively. Nevertheless, differences can be
observed among the two animal species in the IgG sub-
classes to bind FcR, to fix complement or to undergo to
cytokine-induced subclass switching [27]. Despite these
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pattern in mice and humans can be considered quite
similar. In general, it is possible to conclude that in
mice and humans IgG1 (as well as IgG4 in humans) is
associated with a Th2 profile and the other subclasses
are mainly associated with a Th1 profile [28].
As for other infectious diseases, the pattern of IgG
subclass has been shown to play a role in the course of
HIV infection and it has been reported to vary with pro-
gression status. Subjects enrolled in the French Asymp-
tomatic Long-Term (ALT) cohort showed a strong IgG1
responses to Env and Pol antigens as well as a broad
IgG subclass response to p24 [29]. Further studies have
shown that anti-HIV humoral response characterized by
a broad spectrum of IgG subclasses is associated with a
non-progressor status [28,30].
Such observation strongly suggest that, in order to be
protective, a HIV vaccine should elicit a broad and
balanced IgG subclass immune response. So far all the
soluble gp120 glycoprotein based HIV-1 vaccines have
shown to elicit mainly IgG1 subclass antibodies both in
humans and mouse, indicating a TH2s k e w e dr e s p o n s e
[31-34], and strategies to switch to a broader IgG sub-
class profile have been proposed [32,34]. Alternative
vaccine approaches have been shown to induce a more
balanced TH1a n dT H2r e s p o n s e[ 3 5 ]o raT H1s k e w e d
response [36,37]. In particular, adjuvants used in the
vaccine formulation may influence the IgG profile, with
CpG and MPL inducing a TH1 skewed immune
response [38-42] while Al(OH)3 aT H2 profile [43,44].
Virus-like particles (VLPs) developed in our laboratory
are based on the HIV-1 Pr55gag precursor protein
(HIV-VLPs) and display a trimeric gp140 molecule from
an Ugandan HIV-1 isolate of the A clade [45-48]. Such
HIV-VLPs have shown to induce HIV-1-specific CD4+
and CD8+T cell responses as well as cross-clade neutra-
lizing antibodies in immunized Balb/c mice [49,50].
Moreover, the intraperitoneal and intranasal administra-
tion of HIV-VLPs in mice have demonstrated to induce
antibody responses at systemic as well as mucosal (vagi-
nal and intestinal) levels [13,14]. Furthermore, we have
previously reported that baculovirus-expressed HIV-1
VLPs developed in our laboratory induce secretion of
both TH1 and TH2 cytokines in Monocyte-Derived Den-
dritic Cells (MDDC) [51,52] as well as in PBMCs
[53,54].
In order to evaluate whether the pattern of IgG sub-
classes induced by baculovirus-expressed HIV-VLPs
could be broaden and/or skewed toward a more pro-
nounced TH1 profile, immunogenicity studies were per-
formed using the two TH1-skewing adjuvants, CpG
ODN1826 and poly(I:C) [55-57]. In particular, polyI:C is
a synthetic double stranded RNA that potently induces
IL-12 and type I IFNs through activation of innate
immunity via endosomally expressed TLR3 and the
cytoplasmic receptor MDA-5 [58,59]. Induction of type
I IFNs results into DC maturation and B cell activation,
followed by initiation of potent CD4+T cell and
humoral immune responses, as shown in mice [60,61]
and in non-human primates [42,62]. Furthermore, type I
IFNs have been shown to induce, in a mouse model,
cross presentation of proteins to generate CD8+ T cell
responses [63,64].
CpG ODNs are synthetic oligonucleotides containing
unmethylated CpG dinucleotides with specific motifs
recognized by the innate immune system of vertebrates
[65]. These motifs represent the ligand for TLR-9
expressed intracellularly in phagocytic cells [66] and can
induce maturation, differentiation and proliferation of
different immune cell types [67-71]. Upon induction,
immune cells secrete cytokines and chemokines that
create a TH1 biased immune environment [72-75]. Vac-
cines formulated with CpG motifs have been shown to
elicite both cellular and humoral response [76-78].
The results in the present study show that both adju-
vants, and more potently poly(I:C), are able to skew the
immune response to HIV-VLPs toward a TH1 profile.
Material and methods
VLPs preparation
HIV-1 Virus-like Particles expressing on their surface
modified HIV gp140 Clade A were prepared as pre-
viously described [79]. Briefly, HighFive insect cells,
derived from Trichoplusia ni egg cell homogenates
(Invitrogen Inc.), were propagated in SF900 serum-free
medium supplemented with 1% antibiotics (Gibco-BRL)
and 9 × 10
5 cells seeded in a 6-well plate were trans-
fected with 10-20 μg of recombinant bacmid DNA, by
the Cellfectin method (Gibco-BRL). After 72 hr incuba-
tion, recombinant baculovirus released in the superna-
tant of transfected cells (Passage 1) was used to infect 2
×1 0
6 HighFive cells/well and the released recombinant
baculovirus was collected after 72 hr incubation (Passage
2). A further infection step was performed to obtain the
Passage 3 recombinant baculovirus to be used for large-
scale VLPs preparation. HighFive cells were propagated
in suspension and 4 × 10
9 cells were infected with the
P3 recombinant baculovirus at a multiplicity of infection
(M.O.I.) of 5 in a final volume of 100 ml. After 5 hr
incubation in orbital shaker, cells were diluted with
SF900 culture medium to a concentration of 1 × 10
6/ml
and incubated for 96 hrs in orbital shaker. Subsequently,
supernatants were clarified by centrifugation at 2,000 g
for 15 min at 4°C and VLPs were pelleted by ultra-cen-
trifugation at 100,000 g for 75 min through a 25%
sucrose cushion, as previously described [47,80] and
resuspended in TNE buffer (10 mM Tris-HCl, pH 8.0,
100 mM NaCl and 1 mM EDTA).
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For the immunization study, 6 female Balb/c mice of 6-8
weeks old were immunized subcutaneously with 20 μg
of HIV-VLP in combination or not with 20 μgo fC p G
ODN1826 or 100 μg of poly(I:C) (both from InvivoGen)
as adjuvants. Mice received a priming and two homolo-
gous boosts, three weeks apart from each other. Blood
samples were collected with retro-orbital puncture a
week after each injection; sera were heat inactivated and
stored at -80°C until used. Animal experiments were
carried out following internationally recognized guide-
lines and were approved by the Italian Ministry of
Health.
ELISA
All ELISA determinations individually described below
were developed with the following procedure. Positive
reactions were visualized with TMB Ultra 1-step solu-
tion (Thermo Scientific) and stopped with 2N sulfuric
acid. Absorbance was determined at O.D.450 nm and
reactions were considered positive when exceeding the
mean absorbance +3 standard deviations of equal dilu-
tions of pre-immunization sera collected from animals.
The antibody (Ab) levels were evaluated as the geo-
metric mean titer of the last positive dilution of sera
from the animals of each set. In all ELISA pre-immuni-
zation sera have been used as negative control.
Measurement of specific anti-HIV IgG antibodies in mouse
serum
The level of IgG antibodies in sera of immunized mice
was determined by ELISA. Briefly 96-well MICROTEST
assay plates (Becton Dickinson) were coated with 100
ng/well of B clade p24 (NIBSC-CFAR, Catalog
#EVA620) or homologous A clade trimeric gp140 and
incubated overnight at 4°C. Three-fold dilutions of
mouse sera starting at a 1:100 dilution, were added to
each well and incubated 2 hrs at 37°C. Horseradish per-
oxidase (HRP)-conjugated goat anti-mouse IgG (Thermo
Scientific) was added to each well at a concentration of
1 μg/mL (100 ng) and incubated 2 hrs at 37°C.
Determination of anti-gp140 and anti-p24 specific IgG
subclasses
Specific anti-gp140 and anti-p24 IgG subclasses were
determined by ELISA in sera of mice immunized as pre-
viously described. Specific HRP-conjugated goat anti-
mouse IgG1 or biotin-conjugated goat anti-mouse IgG2a,
IgG2b and IgG3 (all from Southern Biotech) were added
individually to each well and incubated for 2 hr at 37°C.
The anti mouse IgG1 was used at a 1:2,000 dilution.
Alternatively, the biotin-conjugated goat anti-mouse
IgG2a,I g G 2b and IgG3 were used at a 1:5,000 dilution
a n dat h i r dH R P - c o n j u g a t e da n t i - b i o t i nA b( C e l l
Signaling) was added to each well at 1:1,000 dilution for
an additional 1 hr incubation at 37°C.
Overtime evaluation of anti-gp140 and anti-p24 specific
humoral immune response
The trend of the humoral immune response during the
immunization protocol was evaluated. At each time
point, three-fold dilutions of pooled sera from immuni-
zation groups were added to each well coated with
recombinant gp140 or p24. Specific anti-mouse HRP-
conjugated IgG was then added at 1 μg/mL concentra-
tion and plates were incubated for 2 hours a 37°C.
TH1: TH2 index calculation
To determine whether the addition of adjuvants in the
immunization protocol induced a TH1 (IgG2a and IgG3)
or TH2 (IgG1) polarization, we proceeded as follows.
The reciprocal value of the titer at last positive dilution
for each IgG subclass was considered for each immuni-
zation protocol. The TH1:TH2 index was then calculated
as ([IgG2a+IgG3]/2)/(IgG1). According to such calcula-
tion, an index value < 1 stands for a TH2p o l a r i z a t i o n ;
an index value > 1 stands for a TH1 polarization.
Statistical analysis
Intergroup comparisons were performed with the
unpaired two-sided Student’s t-test. All P values were
two-tailed and considered significant if less than 0.05.
Results
Immunization with HIV-1 VLP induces specific antibodies
to HIV-1 antigens
In order to determine the effect of CpG ODN1826
and poly(I:C) adjuvants on the humoral response eli-
cited by baculovirus-expressed HIV-VLPs developed in
our laboratory, Balb/c mice were immunized by intra-
dermal route with 20 μg of VLPs alone or formulated
with the two adjuvants. Sera collected after the last
boosting from all immunization groups were heat-
inactivated and evaluated in ELISA against HIV-1 p24
a n dt r i m e r i cg p 1 4 0 .T h er e s u l t ss h o w e dt h a tb o t h
adjuvants were able to enhance the immunogenicity of
HIV-VLPs eliciting a final 1:8,100 (CpG ODN1826)
and 1:24,300 (poly(I:C)) titer of IgG to both p24 and
gp140 (Figure 1). Such results confirm data recently
reported by our Group, showing the enhanced immu-
nogenicity of VLPs when formulated in CpG
ODN1826 [81].
Kinetic of anti HIV-1 humoral immune response
In order to determine how the anti-p24 and anti-gp140
immune responses develop in the course of the immuni-
zation protocol, sera were reacted in ELISA with recom-
binant gp140 or p24 after each antigen administration.
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mals were pooled.
The results for both p24 and gp140 showed that the
trend of total IgG titers is quite similar for sera from
each immunization group, although those from animals
immunized with poly(I:C)-adjuvanted HIV-VLPs showed
a more sustained fashion (Figure 2A and 2B). Concerning
the p24, the formulation of VLPs in either CpG
ODN1826 or poly(I:C) induced an enhancement of total
IgG titers after the third administration, compared to
HIV-VLPs alone (Figure 2B). In particular, the CpG
ODN1826 induced a 3-fold enhancement (1:8,100 vs
1:2,700) and the poly(I:C) induced a 9-fold enhancement
(1:24,300 vs 1:2,700) (p < 0.05). Similar enhancement in
the total IgG titers were observed for the gp140 (Figure
2A).
TH1 polarization induced by HIV-VLPs formulated in
adjuvants
The pattern of IgG subclasses induced by the different
immunization protocols was evaluated by using second-
ary goat anti-mouse antibodies specific for each IgG
subclass.
Sera from animals immunized with HIV-VLPs alone
showed anti-p24 low titers (1:300) of both TH2I g G 1
and TH1 IgG3 subclasses, while no IgG2a or IgG2b
were detected (Figure 3). The formulation of HIV-VLPs
in CpG ODN1826 adjuvant did not enhance IgG1 and
IgG3 titers, but induced a 9-fold enhancement in anti-
p24 IgG2a and IgG2b titers (1:900) compare to HIV-
VLPs alone (Figure 3). In contrast, HIV-VLPs formu-
lated in poly(I:C) adjuvant induced significantly higher
titers of all four IgG subclasses (Figure 3), with the high-
est titers observed for TH1 subclasses (IgG2a = IgG2b >
IgG3 > IgG1).
Similar results were observed for anti-gp140 response
(Figure 4). Sera from animals immunized with HIV-
VLPs alone showed medium/low titers of both TH2
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Figure 1 Evaluation of anti-p24 and anti-gp140 IgG titers
elicited in sera of immunized mice. Three-fold dilutions of heat
inactivated pooled mice sera, collected after the last antigen
administration, were evaluated in ELISA for their reactivity with
recombinant p24 and trimeric gp140. Final total IgG titers are
reported in Figure as log10 of last dilution of sera exceeding the
mean absorbance +3 standard deviations of equal dilution of pre-
immunization sera.
gp140
p24
A
B
Figure 2 Kinetic of anti-p24 and anti-gp140 immune responses.
Pooled sera, from each group of immunized animals, were reacted
in ELISA with recombinant gp140(panel A) or p24(panel B). Total
IgG titers after each antigen administration were calculated for each
group. Titers were scored positive at the last dilution exceeding the
mean absorbance +3 standard deviations of equal dilution of pre-
immunization sera.
Figure 3 Assessment of anti-p24 specific IgG subclasses. Pool of
sera from the last bleeding for each immunization group were
reacted with recombinant p24. Anti-p24 IgG subclasses were
detected with specific goat anti-mouse IgG subclasses. Titers were
scored positive at the last dilution exceeding the mean absorbance
+3 standard deviations of equal dilution of pre-immunization sera.
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detected. However, in contrast to results for anti-p24,
low titers of IgG2b anti-gp140 were detected (Figure 4).
The formulation of HIV-VLPs in CpG ODN1826 adju-
vant induced a 3-to-9-fold enhancement in the IgG2a
and IgG2b titers (1:900) compared to HIV-VLPs alone.
No enhancement effects on IgG1 and IgG3 titers were
observed. In contrast to results on p24, HIV-VLPs for-
mulated in poly(I:C) adjuvant induced significantly
higher titers of only TH1 IgG subclasses, with no
enhancement of IgG1 titers (IgG2a = IgG2b > IgG3 >
IgG1) (Figure 4). The analysis of titers was supported by
statistical significance (p < 0.05).
Such results indicate that antibody profile induced by
HIV-VLPs in mice is TH2 for both p24 and gp140 and
that formulation in either CpG ODN1826 or poly(I:C)
adjuvant results in a TH1 skewed IgG pattern.
TH1: TH2 index calculation
To assess whether the adjuvant formulation elicited a
specific IgG subclass profile or induced an increment in
all subclasses, a TH1:TH2 index was calculated for each
immunization groups. Such index takes into considera-
tion both TH1 IgG2a and IgG3 subclasses compared to
TH2 IgG1 subclass. The TH1:TH2 index showed that, in
sera of animals immunized with HIV-VLPs alone, the
antibody response to p24 and gp140 was TH2p o l a r i z e d
(TH1: TH2 index 0.66 and 0.22, respectively). In contrast,
in sera of mice immunized with adjuvanted HIV-VLPs,
t h ea n t i b o d yr e s p o n s et op 2 4w a sm a r k e d l ys k e w e d
towards a TH1p r o f i l e( T H1: TH2 index > 1), and such
effect was more pronounced when HIV-VLPs were
adjuvanted in poly(I:C) (TH1: TH2 index 6) (Table 1).
Also for gp140, the formulation of HIV-VLPs in poly(I:
C) adjuvant induced a skewing towards a TH1 profile
(TH1: TH2 index 2) (Table 1). IgG2b titers were
excluded from the index calculation because the rela-
tionship between this IgG subclass and TH-polarization
is still debated [82,83].
Discussion
The pattern of IgG subclass has been shown to play a
role in the course of HIV infection and it has been
reported to vary with progression status. In particular, a
strong TH1 polarizing IgG subclasses as well as a broad
IgG subtype response has been associated with long-
term non-progressor status [28-30,84].
In order to determine the pattern of IgG subclasses
induced by HIV-1 antigens packed in particulate struc-
tures as Virus Like Particles and to investigate the mod-
ulation of such pattern by TH1-inducing adjuvants,
Balb/c mice were immunized intradermally with HIV-
VLPs alone or formulated with CpG ODN1826 or poly
(I:C) adjuvants.
Results shown in the present study confirmed the abil-
ity of HIV-VLPs to induce strong humoral immune
response and both adjuvants were able to enhance the
immunogenicity of HIV-VLPs, inducing a 3-9 fold
increase in the total IgG titers for both p24 and gp140.
The kinetic of induced humoral immune response
showed a similar trend in sera from each immunization
group, although the poly(I:C) induced a more sustained
titer.
Evaluation of IgG subclasses demonstrated that HIV-
VLPs alone induced anti-p24 and anti-gp140 IgG1 and
IgG3 subclasses with no IgG2a elicitation. On the con-
trary, CpG ODN1826 and poly(I:C) showed the same
capacity to enhance titers of anti-p24 and anti-gp140
IgG2a and IgG2b subclasses, compared to HIV-VLPs
alone. In addition, only poly(I:C) was able to induce an
enhancement also in IgG1 and IgG3 subclasses,
Figure 4 Assessment anti-gp140 specific IgG subclasses. Pool of
sera from the last bleeding for each immunization group were
reacted with recombinant gp140. Anti-gp140 IgG subclasses were
detected with specific goat anti-mouse IgG subclasses. Titers were
scored positive at the last dilution exceeding the mean absorbance
+3 standard deviations of equal dilution of pre-immunization sera.
Table 1 TH1:TH2 index for p24 and gp140
p24 VLP VLP+ODN1826 VLP+poly(I:C)
IgG1 (TH2) 300 300 900
IgG2a (TH1) 100 900 8,100
IgG3 (TH1) 300 300 2,700
TH1:TH2 index 0.66 2 6
gp140 VLP VLP+ODN1826 VLP+poly(I:C)
IgG1 (TH2) 900 900 900
IgG2a (TH1) 100 900 2,700
IgG3 (TH1) 300 300 900
TH1:TH2 index 0.22 0.66 2
The index has been calculated as described in Materials and Methods section.
Index < 1 = TH2 polarization. Index > 1 = TH1 polarization.
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immune response. Such results indicate that antibody
profile induced by HIV-VLP in mice is TH2 for both
p24 and gp140 and that formulation in both adjuvants
results in a TH1 skewed IgG pattern. In particular, in
our experimental model, poly(I:C) scores as the most
potent in re-directing the TH pattern, in agreement to
previous observations [85,86].
Such finding is further confirmed by the TH1:TH2
index which evaluates the ratio between both TH1a s s o -
ciated IgG subclasses (IgG2a and IgG3) and TH2a s s o -
ciated (IgG1) subclass. Indeed, considering that an index
v a l u e>1s t a n d sf o raT H1 polarization, the index in
sera from animals immunized with poly(I:C)-adjuvanted
HIV-VLPs scored the highest.
Our results confirm that HIV-VLPs represent an effec-
tive antigenic presentation and delivery system to prime
the humoral immune response, eliciting mainly IgG1
subclass antibodies (TH2 profile) with other subclasses
represented at low titer (IgG2b and IgG3) or not present
at all (IgG2a). We demonstrated that TH1-inducing
adjuvants, and in particular the poly(I:C), were able to
broaden the IgG subclasses response and to re-direct
the immune response toward a TH1-biased pattern. In
particular, HIV-VLPs formulated in poly(I:C) adjuvant
elicited the highest titer of IgG3 subclass which has
been claimed to mediate the HIV neutralization in sera
from HIV-infected individuals [87,88]. However all the
known broadly neutralizing antibody (i.e. IgGb12,
VRCO1, 2G12, 2F5 and 4E10) belong to IgG1 antibody
subclass with the exception of 447 that is an IgG3 anti-
body. Nevertheless, crystallographic analysis of such
broadly neutralizing antibodies reveal molecular struc-
tures (i.e., longer complementary determining region
(CDR) H3) which suggest that these IgG1 monoclonal
antibodies show properties similar to the IgG3 subclass
[89-91]. These studies indicate that molecular character-
istics of the IgGs (i.e., flexibility of the antibody, mobility
of the F(ab) or antigen binding site) are relevant for an
efficient neutralizing activity of HIV.
In this perspective, studies focused on the formulation
of vaccine candidates in adjuvants able not only to
enhance immunogenicity but also to re-direct IgG sub-
class response, may represent a key aspect in the vacci-
nology field. In fact, adjuvant formulations can be
tailored to enhance the required immune response (anti-
body, cell mediated, mucosal immunity) appropriate for
individual causative infectious agents [92].
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